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Osteosarcoma (OSA) is an aggressive mesenchymal bone
tumor that affects ~3000 children annually in the USA.
Treatment consists of chemotherapy, radiotherapy and
radical surgery. Despite treatment, metastatic disease is
common and results in 30-40% mortality within 5 years.
Novel therapies that prevent metastatic disease are
required to improve outcome. HER2/Neu is a tyrosine
kinase receptor belonging to the EGFR family. It is
expressed in ~40% of pediatric OSA and is linked to
reduced chemotherapeutic response, high metastatic rates
and short overall survival time. Recent reports indicate
that HER2/Neu is expressed on OSA tumor initiating
cells and that immune targeting of HER2/Neu delays
metastatic disease.
Large breed dogs spontaneously develop OSA that
recapitulates many aspects of pediatric OSA including
histologic heterogeneity, aggressive local disease and early
metastases. At diagnosis, 95% of dogs have micrometa-
static disease and despite amputation and chemotherapy,
the median survival time is 10 months with most dogs
euthanized due to progressive metastatic disease. As in
pediatric OSA, HER2/Neu is expressed in ~40% of canine
appendicular OSA making dogs a relevant model to eval-
uate the effects of HER2/Neu targeted immune therapy
on metastatic disease prevention.
We performed a Phase I clinical trial to evaluate the
safety and efficacy of an attenuated, recombinant Lis-
teria monocytogenes (Lm) expressing a chimeric human
HER2/Neu fusion protein (ADXS31-164) to prevent
metastatic disease in dogs with HER2/Neu+ appendicular
OSA. Lm secretes a pore-forming lysin, listeriolysin
O (LLO) that enables it to escape the phagosome and
access the class I processing machinery of antigen-
presenting cells. As such, recombinant Listeria, engi-
neered to express tumor antigens fused to LLO, induce
potent tumor-specific CD8 T cells that mediate tumor
regression in murine models. Seventeen dogs with HER2/
Neu+ OSA that had undergone amputation and carbo-
platin chemotherapy received 1 × 108, 5 × 108, 1 × 109
or 3 × 109 CFU of ADXS31-164 intravenously every
3 weeks for three administrations. ADXS31-164-associated
toxicities were low grade and transient. Treated dogs failed
to develop pulmonary metastatic disease and showed
a statistically significant increase in overall survival com-
pared to a historical HER2/Neu+ control group.
14/17 treated dogs are still alive; median survival in HER2/
Neu+ control dogs (n = 13) was 316 days (p = 0.032).
ELISpot assays are underway to evaluate ADXS31-164-
associated HER2/Neu specific immune responses. Our
results indicate that ADXS31-164 significantly delays
metastatic disease in a clinically relevant, spontaneous
model and have important implications for pediatric OSA.
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